Mandate

Vinge advises IBT on share issues

November 24, 2017

Vinge advises Infant Bacterial Therapeutics AB (publ) (Nasdaq First North Premier) in connection with a combined directed issue and rights offering of approximately SEK 545 million.

The Vinge team includes Erik Sjöman, Christian Lindhé, Kristoffer Franzkeit, Ludvig Frithiof and Astrid Karlsson.

Related

Vinge has advised Studentbostäder i Norden AB in connection with its rights issue

Vinge has advised Studentbostäder i Norden AB (publ), a real estate company whose shares are listed on Nasdaq First North Premier Growth Market, in connection with an oversubscribed rights issue amounting to approximately SEK 145 million before deduction of transaction costs.
April 25, 2025

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Carlstedt & Lindh AB and Brahe Revisionsbyrå AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of Carlstedt & Lindh AB and Brahe Revisionsbyrå AB
April 24, 2025

Vinge advises Biotage in connection with RWK Bidco’s public tender

On 22 April 2025, RWK Bidco AB, a newly formed company indirectly wholly owned by KKR Funds, announced a public tender offer to the shareholders in Biotage AB to tender all ordinary shares in Biotage to RWK Bidco at a price of SEK 145 in cash per ordinary share.
April 22, 2025